Augurex Presents Novel 14-3-3eta Biomarker Data for Axial Spondyloarthritis Diagnosis at ACR Convergence 2025
Key Insights
Augurex Life Sciences (search) will present new clinical data on autoantibodies to 14-3-3eta (search) as a diagnostic biomarker for axial spondyloarthritis (search) at ACR Convergence 2025.
The research demonstrates the biomarker's ability to discriminate between radiographic and non-radiographic axial spondyloarthritis (search) versus mechanical back pain (search) and healthy controls.
The 14-3-3eta (search) biomarker improves discriminative performance when combined with existing markers CRP (search) and HLA-B27 (search) for differentiating radiographic axSpA from mechanical back pain (search).
Augurex Life Sciences (search) will showcase new clinical data on a novel diagnostic biomarker for axial spondyloarthritis (search) (axSpA) at the American College of Rheumatology Convergence 2025, taking place October 24-29 in Chicago. The company's presentations focus on autoantibodies to 14-3-3eta (search) protein as a tool to improve diagnosis of this often-misdiagnosed autoimmune condition.
Novel Biomarker Shows Promise for Diagnostic Discrimination
Professor Raj Sengupta will present new data demonstrating the use of autoantibodies to 14-3-3eta (search) in discriminating between radiographic and non-radiographic axial spondyloarthritis (search) compared to both mechanical back pain (search) and healthy controls. The oral presentation, titled "Autoantibodies to 14-3-3 eta: A Novel Diagnostic Biomarker for Axial Spondyloarthritis," is scheduled for Tuesday, October 28, 2025, from 3:45-4:00 p.m. Central Time.
Enhanced Performance with Existing Biomarkers
Additional research to be presented shows that the 14-3-3eta (search) autoantibody biomarker improves the discriminative performance of established markers C-reactive protein (CRP (search)) and HLA-B27 (search) when differentiating people with radiographic axSpA from those with mechanical back pain (search). This combination approach could provide clinicians with more accurate diagnostic tools.
A third presentation will evaluate the diagnostic utility of 14-3-3eta (search) autoantibodies using a multiplex assay approach, further exploring the biomarker's clinical applications in axial spondyloarthritis (search) diagnosis.
Addressing Critical Diagnostic Delays
"With the significant prevalence of chronic back pain (search) within our society, and the protracted diagnostic delays patients face with axial spondyloarthritis (search), we are excited to share these important data at the upcoming ACR Convergence conference," said Neil Klompas, Chief Executive Officer of Augurex. The company aims to provide primary care physicians and rheumatologists with new tools to eliminate diagnostic delays in axSpA, enabling patients to access appropriate therapies earlier in their disease course.
Commercial Applications
Augurex's lead diagnostic test detecting the 14-3-3eta (search) protein is currently available as JOINTstat (search)® in Canada and Great Britain for inflammatory disease diagnosis and management, including rheumatoid arthritis (search). The Anti-14-3-3eta Multiplex analyte-specific reagents are available as SPINEstat (search) in these markets, specifically targeting axial spondyloarthritis (search) diagnosis. In the United States, the analyte-specific reagents are available for purchase by clinical laboratories as components of laboratory-developed diagnostic tests.